Alper Toker.

lung cancer, mediastinal surgery, tracheal reconstructions and Robotics, West Virginia University Heart and Vascular Institute, Basketball TBL 1986-1992

[Alper Toker. @TokerAlper]

STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY - The Annals of Thoracic Surgery https://t.co/tfpjKwFGUq

[Dr. Kıvılcım Kayabalı @KKAYABALI]

“AI, Human Cognition and Knowledge Collapse”
Daron Acemoglu, Dingwen Kong ve Asuman Ozdaglar (3 MIT araştırmacısı) tarafından 20 Şubat 2026’da yayımlanan makalede yazarlar başarılı kararların iki tamamlayıcı faktör gerektirdiği dinamik bir model kuruyorlar; topluluk düzeyinde paylaşılan “genel bilgi” ile bireysel, bağlama özgü bilgi. İnsanın öğrenme çabası hem kişiye özel bir sinyal üretiyor hem de toplumun genel bilgi stokuna katkıda bulunan “ince” bir kamusal sinyal yaratıyor. 
YZ ise bağlama özgü tavsiyeler sunarak insan çabasının yerini alıyor. YZ’nin doğruluğu belirli bir eşiği aştığında kişiselleştirilmiş önerilere karşın genel bilgi çöküyor. 
Model aynı zamanda refahın tek düze olmadığını gösteriyor: mütevazı düzeyde YZ yardımı faydalı, ancak aşırı doğruluk çöküşü tetikleyebiliyor. Optimum düzenlemenin, YZ çıktılarının kasıtlı olarak “bulanıklaştırılmasını” içerebileceğini öne sürüyorlar. Yani çok iyi bir YZ, paradoksal biçimde toplumu çok olumsuz etkileyebilir.

[RegulatingAI @RegulatingAI]

Healthcare is at an inflection point. AI is rewriting how we diagnose, treat, and deliver care. But who sets the rules? Who bears the risk? And who gets left behind?

In our next episode, @ashishkjha , Dean of @Brown_SPH , sits down with @FSagasti , former President of Peru and @ClubdeMadrid Member, to confront the questions the industry is not asking loudly enough.

The Great AI Healthcare Reckoning is coming soon to the Regulating AI Podcast.
Follow to be notified when it drops.

#RegulatingAI #AIHealthcare #HealthPolicy #ArtificialIntelligence #AIGovernance #HealthcareAI #PublicHealth #AIRegulation #KnowledgeNetworks #ClubDeMadrid #ComingSoon

[Dr. Estela Rodriguez @Latinamd]

Here are my own #ASCO26 Top 10 🫁 Lung Cancer Abstracts based on potential clinical impact — although there is so much exciting and innovative science being presented across the field. Looking forward to the discussions, debates, and future directions these data may inspire. #LungCancer

[Hari B. Keshava @hari_keshava]

A whole new era with neo adj Chemo and tki!

[JTO & JTO CRR @JTOonline]

Thoracic imaging is redefining #lungcancer care. Advances in CT, PET, MRI, radiomics, radiogenomics, and AI are helping clinicians detect disease earlier, personalize therapy, and better assess response to treatment.

Read more: https://t.co/Uh9pb1MyTg #JTO20

[Isabelle Opitz @IsaOpitz]

Exciting ! 🚀

Our phase III SalVage trial is now recruiting across multiple hospitals. This study explores whether adding local ablative treatment (surgery and/or radiotherapy) to standard therapy can improve survival and quality of life in patients with advanced NSCLC (stage IV).

For patient referrals, please send us an email [email protected] and [email protected]
Home | https://t.co/4elPG0D3dF

@Mat_Guc @MdCurioni @HeldUlrike @UszDidi @HillingerSven @OliviaLauk Gian-Marco Monsch @senbak68 @raph_werner Albana Rexhepaj

#NSCLC #ClinicalTrial #Oncology #PatientCare #salVage

[CTSNet @ctsnetorg]

The new and improved CTSNet website is now live!

Explore the new site today! When you need to return to the home page, simply click the new CTSNet logo! Helpful guides on the new features are now live!

Visit the new website here: https://t.co/NqomedqYHo

[AATS @AATSHQ]

Editor's Choice Article in #JTCVS: Lobectomy improves disease-free survival over sublobar resection for high-risk stage IA #NSCLC. Learn more from researchers at @MSK_Thoracic @MSKCancerCenter: https://t.co/B3v7EUt6ur

@caso_raul @KatherineGrayMD

[Alper Toker. @TokerAlper]

Istanbul at Harvard Museum.

[Mara Antonoff, MD, FACS @maraantonoff]

Findings from surgery after systemic tx in NSCLC with pleural mets:

📊 Imaging predicted pleural response, offering needed criteria in a space where clear benchmarks have been lacking

📈 Most pts (70.8%) had no residual pleural disease at surgery

🔗 https://t.co/qMNUgTp13a

[JTO & JTO CRR @JTOonline]

MRD detection is emerging to guide adjuvant therapy and monitor recurrence in early-stage NSCLC. Tan et al. offer a framework for its clinical implementation. Read more: https://t.co/3S0CZi0IEX

#LungCancer #NSCLC

[Houstorian @Houstorian]

Today in 1970, feuding Houston surgeons Denton Cooley and Michael DeBakey appear on the cover of Life Magazine.

[ESTS @thoracic]

Whether you are an established leader or an emerging talent, Athens will be the perfect setting to learn, contribute, and grow within our dynamic specialty.

We look forward to welcoming you!
🔗https://t.co/kqdf1zIeRR

#ESTS2026 #ThoracicSurgery

[Hari B. Keshava @hari_keshava]

It's THORACIC THURSDAY!

Here's our latest episode of Thinking Thoracic with @AworiHayanga talking abou Lung volume reduction surgery, end-stage COPD and the latest data!!

#thinkingthoracic #thoracicthursday
@STS_CTsurgery @TheHub_STS @ErinGillaspie @ChiFuJeffYang

[Alper Toker. @TokerAlper]

Not All T4 Patients Should Be Considered Equal: Non-Small Cell Lung Cancer Heterogeneity and Surgical Outcome - Annals of Thoracic Surgery Short Reports https://t.co/QigrEThhVx

[AATS @AATSHQ]

When is wedge resection good enough? Researchers at Tokyo recently published survival outcomes and nodal involvement of ground-glass–dominant stage IA #NSCLC. Read more in #JTCVS Open: https://t.co/gLUot991Oq